Rna Diagnostics Inc. announced today that Paul Lucas, an accomplished veteran of the Life Sciences industry, has joined the Company’s Board of Directors.

“Paul brings a wealth of proven business and Life Science innovation insight to Rna Diagnostics,” said Dr. Ken Pritzker, President and CEO of Rna Diagnostics Inc. “He has been a member of our Business Advisory Board since 2012 and consistently shared his significant expertise and guidance. We are delighted to have him join our board.”

“I am very pleased to join the board of directors of Rna Diagnostics. Over the past 3 years, as business adviser, I have had the satisfaction of seeing the RDA™ technology evolve from scientific discovery to its current status of early clinical adoption. I look forward to working with the board and management to help bring RDA into full commercial acceptance by cancer clinics around the world,” said Paul Lucas.

Mr. Lucas served as President and CEO of GlaxoSmithKline Canada from 1994 until he retired in 2012. Previous to joining Glaxo Canada in 1986, he held progressive management positions at Eli Lilly Canada and McNeil Pharmaceutical.
Mr. Lucas also served as Chairman of the Board of Directors for TM Bioscience, a member of the Boards of Biochem Pharma, the Toronto Regional Research Alliance, Montreal inVivo, and AllerGen.

In addition he was a member of the Principal’s Advisory Council of the University of Toronto at Mississauga, and a member of the Board of Trustees of Queen’s University. He also served as Chairman of the Board of Directors of Canada’s Research-Based Pharmaceutical Companies (Rx&D) for three terms.

Currently Mr. Lucas is a member of the Board of Directors of the Ontario Genomics Institute, ABcann Medicinals Inc. and EcoSynthetix Inc, Chair of the Board of Induran Ventures Inc. and Chair of the Board of Life Sciences Ontario.

He received his BSc (Honours) in Biology and Chemistry from Queen’s University, and obtained his Chartered Directors designation (CDir) from the Directors College, a joint venture of McMaster University and the Conference Board of Canada, in 2009.

About Rna Diagnostics Inc.
Rna Diagnostics is a cancer diagnostics company providing a platform of prognostic biomarker tools to help improve the lives of cancer patients treated with chemotherapy. Founded in 2010, Rna Diagnostics’ first product is  The RNA Disruption Assay™ (RDA™) providing physicians with an evaluation of how individual patients are responding to chemotherapy as early as 14 days after 1stcycle of treatment. If chemotherapy is working, the physician and patient can continue treatment with confidence. If chemotherapy is not working, physicians may consider alternate therapies. For patients, this means avoiding harmful side effects and the possibility for improved survival outcomes. www.rnadiagnostics.com. ​